Newly developed nomograms provide accurate predictions for patients with oropharyngeal cancer

(NRG Oncology) NRG Oncology researchers recently developed and validated a nomogram that can predict 2-year and 5-year overall survival (OS) and progression-free survival (PFS) for patients with local-regionally advanced oropharyngeal squamous cell carcinoma (OPSCC) treated primarily with radiation-based therapy. This nomogram was developed with data from clinical trials NRG Oncology/RTOG 0129 and 0522. Results were published online in the Journal of Clinical Oncology on Aug. 4, 2017.